COVID-19: Emergence, Spread, Possible Treatments, and Global Burden

Raghuvir Keni, Anila Alexander, Pawan Ganesh Nayak, Jayesh Mudgal, Krishnadas Nandakumar, Raghuvir Keni, Anila Alexander, Pawan Ganesh Nayak, Jayesh Mudgal, Krishnadas Nandakumar

Abstract

The Coronavirus (CoV) is a large family of viruses known to cause illnesses ranging from the common cold to acute respiratory tract infection. The severity of the infection may be visible as pneumonia, acute respiratory syndrome, and even death. Until the outbreak of SARS, this group of viruses was greatly overlooked. However, since the SARS and MERS outbreaks, these viruses have been studied in greater detail, propelling the vaccine research. On December 31, 2019, mysterious cases of pneumonia were detected in the city of Wuhan in China's Hubei Province. On January 7, 2020, the causative agent was identified as a new coronavirus (2019-nCoV), and the disease was later named as COVID-19 by the WHO. The virus spread extensively in the Wuhan region of China and has gained entry to over 210 countries and territories. Though experts suspected that the virus is transmitted from animals to humans, there are mixed reports on the origin of the virus. There are no treatment options available for the virus as such, limited to the use of anti-HIV drugs and/or other antivirals such as Remdesivir and Galidesivir. For the containment of the virus, it is recommended to quarantine the infected and to follow good hygiene practices. The virus has had a significant socio-economic impact globally. Economically, China is likely to experience a greater setback than other countries from the pandemic due to added trade war pressure, which have been discussed in this paper.

Keywords: 2019-nCoV; COVID-19; SARS; SARS-CoV-2; coronavirus; pandemic.

Copyright © 2020 Keni, Alexander, Nayak, Mudgal and Nandakumar.

Figures

Figure 1
Figure 1
Timeline of COVID-19 progression (–32).
Figure 2
Figure 2
Total confirmed COVID 19 cases as of May 2020 (33).
Figure 3
Figure 3
Case fatality rate by age in selected countries as of April 2020 (33).
Figure 4
Figure 4
Case fatality rate in selected countries (33).
Figure 5
Figure 5
Population share above 70 years of age (33).

References

    1. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA. (1967) 57:933–40. 10.1073/pnas.57.4.933
    1. Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis. (2005) 191:492–8. 10.1086/428138
    1. Stöhr K. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet. (2003) 361:1730–3. 10.1016/S0140-6736(03)13376-4
    1. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. . Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. (2003) 361:1319–25. 10.1016/S0140-6736(03)13077-2
    1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. (2015) 386:995–1007. 10.1016/S0140-6736(15)60454-8
    1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. (2012) 367:1814–20. 10.1056/NEJMoa1211721
    1. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. (2009) 7:439–50. 10.1038/nrmicro2147
    1. Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, et al. . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. (2003) 426:450–4. 10.1038/nature02145
    1. Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, et al. . Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. (2013) 503:535–8. 10.1038/nature12711
    1. Wang M, Hu Z. Bats as animal reservoirs for the SARS coronavirus: Hypothesis proved after 10 years of virus hunting. Virol Sin. (2013) 28:315–7. 10.1007/s12250-013-3402-x
    1. Diamond Princess Cruise Ship in Japan Confirms 99 New Coronavirus Cases | World news | The Guardian Available online at: (accessed February 17, 2020).
    1. Diamond Princess Coronavirus & Quarantine Updates - Notices & Advisories - Princess Cruises Available online at: (accessed February 17, 2020).
    1. Gorbalenya AE, Baker SC, Baric RS, Groot RJ, de Drosten C, Gulyaeva AA, et al. . The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:536–44. 10.1038/s41564-020-0695-z
    1. Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol. (2020) 7:jmv.25682. 10.1002/jmv.25682
    1. Cyranoski D. Did pangolins spread the China coronavirus to people? Nature. (2020) 10.1038/d41586-020-00364-2
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. (2020) 395:565–74. 10.1016/S0140-6736(20)30251-8
    1. Wassenaar TM, Zou Y. 2019_nCoV: Rapid classification of betacoronaviruses and identification of traditional Chinese medicine as potential origin of zoonotic coronaviruses. Lett Appl Microbiol. (2020) 70:324–48. 10.1111/lam.13285
    1. Velavan TP, Meyer CG. The Covid-19 epidemic. Trop Med Int Heal. (2020) 25:278–80. 10.1111/tmi.13383
    1. Guarner J. Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol. (2020) 153:420–21. 10.1093/ajcp/aqaa029
    1. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. . Bats are natural reservoirs of SARS-like coronaviruses. Science. (2005) 310:676–9. 10.1126/science.1118391
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7
    1. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. . A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. (2015) 21:1508–13. 10.1038/nm.3985
    1. COVID-19 Coronavirus Epidemic has a Natural Origin—ScienceDaily Available online at: (accessed April 22, 2020).
    1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. (2020) 26:450–2. 10.1038/s41591-020-0820-9
    1. Prioritizing Diseases for Research and Development in Emergency Contexts Available online at: (accessed April 22, 2020).
    1. Albariño CG, Guerrero LW, Jenks HM, Chakrabarti AK, Ksiazek TG, Rollin PE, et al. . Insights into Reston virus spillovers and adaption from virus whole genome sequences. PLoS ONE. (2017) 12:e0178224. 10.1371/journal.pone.0178224
    1. Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng L, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv. (2020). 10.2139/ssrn.3578153
    1. Stefanelli P, Faggioni G, Lo Presti A, Fiore S, Marchi A, Benedetti E, et al. . Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. Eurosurveillance. (2020) 25:2000305. 10.2807/1560-7917.ES.2020.25.13.2000305
    1. Yadav P, Potdar V, Choudhary M, Nyayanit D, Agrawal M, Jadhav S, et al. . Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. (2020) 151:200–9. 10.4103/ijmr.IJMR_663_20
    1. WHO | Coronavirus disease 2019 (COVID-19) Situation Report – 26 Beijing (2020). Available online at: (accessed February 16, 2020).
    1. WHO | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) World Health Organization (2020).
    1. WHO | Summary of Probable SARS Cases With Onset of Illness From 1 November 2002 to 31 July 2003 World Health Organization (2015).
    1. Worldometer Coronavirus cases. Worldometer. (2020) 1−22.
    1. Update on the Outbreak of New Coronavirus Pneumonia as of 24 hours on 15 February Beijing (2020). Available online at: (accessed February 16, 2020).
    1. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. (2020) 26. 10.3201/eid2607.200282
    1. 83% of India's Coronavirus Patients Are Below the Age of 50: Health ministry data - India News Available online at: (accessed April 23, 2020).
    1. 42% of Coronavirus Patients in 21-40 age bracket: Govt Available online at: (accessed April 23, 2020).
    1. Why COVID-19 Case Counts Are so Low in Singapore Hong Kong and Taiwan | Advisory Board Daily Briefing Available online at: (accessed April 29, 2020).
    1. Coronavirus: Why so Few Deaths Among Singapore's 14000 Covid-19 Infections? | South China Morning Post Available online at: (accessed April 29, 2020).
    1. Stafford N. Covid-19: Why Germany's case fatality rate seems so low. BMJ. (2020) 7:369. 10.1136/bmj.m1395
    1. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. . Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med. (2020) 382:970–1. 10.1056/NEJMc2001468
    1. Coronavirus pandemic | 80% of COVID-19 Cases Either Asymptomatic or Show Mild Symptoms Health ministry - . Available online at: (accessed April 24, 2020).
    1. WHO | Q&A on Coronaviruses Available online at: (accessed February 16, 2020).
    1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. (2020) 382:929–36. 10.1056/NEJMoa2001191
    1. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. (2020) 5:335–37. 10.1016/S2468-1253(20)30048-0
    1. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. . Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. (2020) 395:809–15. 10.1016/S0140-6736(20)30360-3
    1. Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. In: Coronaviruses: Methods and Protocols (New York: Springer; ), 1–23. 10.1007/978-1-4939-2438-7_1
    1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. (2020) 92:418–23. 10.1002/jmv.25681
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Mü MA, Drosten C, Pö S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80. 10.1016/j.cell.2020.02.052
    1. Cheng VCC, Chan JFW, To KKW, Yuen KY. Clinical management and infection control of SARS: Lessons learned. Antiviral Res. (2013) 100:407–19. 10.1016/j.antiviral.2013.08.016
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. . Diagnosing COVID-19: the disease and tools for detection. ACS Nano. (2020) 14:3822–35. 10.1021/acsnano.0c02624
    1. Testing, | CDC,. Available online at: (accessed April 29, 2020).
    1. Advice on the Use of Point-of-Care Immunodiagnostic Tests for COVID-19 Available online at: (accessed April 29, 2020).
    1. Zhang Yanping. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. (2020) Available online at: (accessed February 18, 2020).
    1. Petersen R, Pan L, Blanck HM. Racial and ethnic disparities in adult obesity in the United States: CDC's tracking to inform state and local action. Prev Chronic Dis. (2019) 16:180579. 10.5888/pcd16.180579
    1. Wang L, Southerland J, Wang K, Bailey BA, Alamian A, Stevens MA, et al. . Ethnic differences in risk factors for obesity among adults in California, the United States. (2017) 2017:2427483. 10.1155/2017/2427483
    1. Covid-19 Causes Sudden Strokes in Young Adults Doctors Say - CNN Available online at: (accessed April 24, 2020).
    1. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. . Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. (2020) 1–4. 10.1111/jth.14828
    1. Lancet T, Medicine R. Comment Understanding pathways to death in patients with. Lancet Respir Med. (2020) 2019:2019–21. 10.1016/S2213-2600(20)30165-X
    1. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. (2020) 323:1775–6. 10.1001/jama.2020.4683
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/S0140-6736(20)30566-3
    1. Doctors Warn COVID-19 Might Cause Strokes in Young Adults Available online at: (accessed April 24, 2020).
    1. “Solidarity” Clinical Trial for COVID-19 Treatments Available online at: (accessed April 23, 2020).
    1. Search, of: COVID-19 - List Results - . Available online at: (accessed May 1, 2020).
    1. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, et al. . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. (2014) 58:4875–84. 10.1128/AAC.03011-14
    1. Tai DYH. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. (2007) 36:438–43.
    1. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. . Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. (2020) 11:222. 10.1038/s41467-019-13940-6
    1. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. (2020) 14:72–73. 10.5582/bst.2020.01047
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. 10.1038/s41422-020-0282-0
    1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. . Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. (2005) 2:1–0. 10.1186/1743-422X-2-69
    1. Cramer CL, Patterson A, Alchakaki A, Soubani AO. Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgrad Med. (2017) 129:493–9. 10.1080/00325481.2017.1285677
    1. Plaquenil™ Hydroxychloroquine Sulfate Tablets USP Description Available online at: (accessed April 21, 2020).
    1. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. (2020) 10.1101/2020.04.16.20065920
    1. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Ghasemian R, et al. Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis. medRxiv. (2020) 10.1101/2020.04.14.20065276
    1. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. (2020) 19:149–50. 10.1038/d41573-020-00016-0
    1. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. . Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. (2016) 531:381–5. 10.1038/nature17180
    1. Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv. (2020) 10.1101/2020.04.15.043166
    1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. 10.1016/S0140-6736(20)31022-9
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282
    1. Search, of: Lopinavir, Ritonavir, | COVID - List Results - . Available online at: (accessed April 23, 2020).
    1. Bhatnagar T, Murhekar M, Soneja M, Gupta N, Giri S, Wig N, et al. . Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. (2020) 151:184–9. 10.4103/ijmr.IJMR_502_20
    1. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, et al. . Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. (2005) 56:919–22. 10.1093/jac/dki346
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. . Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. (2020) 323:1582–9. 10.1001/jama.2020.4783
    1. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. . High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. (2020) 7:1–6. 10.1093/ofid/ofaa102
    1. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. (2020) 138745:1–22. 10.1172/JCI138745
    1. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. . Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. (2020) 10.1002/jmv.25882
    1. Recommendations for Investigational COVID-19 Convalescent Plasma | FDA Available online at: (accessed April 23, 2020).
    1. Search, of: plasma | Interventional Studies | COVID - List Results - . Available online at: (accessed April 23, 2020).
    1. Infection Prevention and Control Available online at: (accessed February 17, 2020).
    1. Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. (2020) 27:taaa020. 10.1093/jtm/taaa020
    1. Press Information Bureau AYUSH Advisory for Corona virus Press Inf Bereau. Available online at: (accessed February 17, 2020).
    1. CanSino, Biologics : China Announces First Human Trials of Covid-19 Vaccine | MarketScreener, Available online at: (accessed April 7, 2020).
    1. Safety, and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection - Full Text View - . Available online at: (accessed April 7, 2020).
    1. NIH, Clinical Trial of Investigational Vaccine for COVID-19 Begins | National Institutes of Health (NIH), Available at: (accessed April 7, 2020).
    1. Novel, Coronavirus vaccine manufacturing contract signed — The Jenner Institute, Available online at: (accessed April 7, 2020).
    1. Xie L, Sun C, Luo C, Zhang Y, Zhang J, Yang J, et al. SARS-CoV-2 and SARS-CoV Spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development. bioRxiv [Preprint]. (2020). 10.1101/2020.02.16.951723
    1. The Global Economic Impact of the Coronavirus Outbreak – Harvard Gazette Available online at: (accessed February 17, 2020).
    1. Shimizu K. 2019-nCoV, fake news, and racism. Lancet. (2020) 395:685–6. 10.1016/S0140-6736(20)30357-3
    1. ROHDE RODNEY. 2019 Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus. Am Soc Microbiol. (2020). Available online at:
    1. Virus-free Indonesia more threatened by COVID-19 than Singapore Malaysia: Survey - World - The Jakarta Post Available online at: (accessed February 18, 2020).
    1. Japan, May Lose $1,.29 Billion in Tourism Revenue Due to COVID-19 Outbreak | The Japan Times. Available online at: (accessed February 18, 2020).
    1. Coronavirus's Effect on Tourism Will Carry Into 2021 Experts Say - Bloomberg Available online at: (accessed February 18, 2020).
    1. The, week in charts - The cost of covid-19 | Graphic detail | The Economist,. Available online at: (accessed February 17, 2020).
    1. coronavirus: Covid-19 Impact: Pharma Companies Feel the Pain as Prices of Key Inputs Shoot Up - The Economic Times Available online at: (accessed February 17, 2020).
    1. Coronavirus Outbreak: Paracetamol Prices Jump 40% In India As Coronavirus Shuts Down China Available online at: (accessed February 18, 2020).
    1. The coronavirus could cripple China's economy for longer than Wall Street wants to believe | Business Insider India Available online at: (accessed February 17, 2020).
    1. Viral Slowdown - How China's Coronavirus Epidemic Could Hurt the World Economy | Leaders | The Economist Available online at: (accessed February 17, 2020).
    1. China's Economic Battle With COVID-19 | The ASEAN Post Available online at: (accessed February 17, 2020).
    1. The Coronavirus Could Cost China's Economy $60 Billion this Quarter - CNN. Available online at: (accessed February 18, 2020).

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa